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Abstract
Chronic hepatitis B (CHB) is major global health problem. In China, where about 120,000,000
persons are chronically infected, CHB has been treated for centuries with traditional Chinese
medicines (TCM). The aim of this review was to summarize and meta-analyze critically the
results of randomized, controlled, clinical trials (RCTs) of TCM formulations reported from China
in 1998--2008 for treatment of CHB. RCTs comparing either TCM formulations alone or in
combination with interferon or lamivudine (IFN/LAM) versus IFN or LAM were included. The
Chinese electronic databases were searched. The methodological quality of RCTs was assessed by
the Jadad-scale. Results: (i) TCM had a greater beneficial effect (p = 0.0003) than IFN and
slightly better effect (p = 0.01) than LAM on normalization of serum ALT. (ii) TCM had a similar
beneficial effect when compared with IFN or LAM for CHB on antiviral activity as evidenced by
the loss of serum HBeAg and HBV DNA. (iii) TCM enhanced IFN and LAM anti-viral activities
and improvements of liver function. Quality of many studies was poor; often, reports lacked
information regarding methods of randomization or blinding, and adverse events. In conclusion,
some TCM seem effective as alternative remedies for patients with CHB suggesting that further
study of TCM in the treatment of CHB is warranted, both in pre-clinical models of HBV infection
and in higher quality RCTs world-wide.
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Chronic hepatitis B (CHB) is a major global health problem. Worldwide, more than two
billion people have been infected the hepatitis B virus (HBV), and approximately 400
million people are chronic carriers of the virus. Chronic infection with HBV can
significantly impair the quality of life and life expectancy of patients because of the
potential for disease progression, which can lead to fibrosis, cirrhosis, liver failure, and
hepatocellular carcinoma. It is estimated that worldwide more than 600,000 individuals die
from HBV-related liver disease each year 1. In China alone, there are at least 120,000,000
individuals carrying HBV 2.
Traditional Chinese Medicines and Liver Diseases in China
The ‘Yellow Emperor’s Internal Classic’, an ancient book containing records of traditional
Chinese medicines (TCM), indicates that TCM have been used to treat chronic liver disease
in China at least since 475 BCE. Today, TCM are still used extensively for the treatment of
CHB in China. Thousands of different herbs have been used in numerous TCM formulations
(mixtures of different herbs) for the treatment of CHB. These TCM formulations are based
on the collective wisdom of Chinese clinicians and practitioners, coupled with centuries of
accumulated experience working with these herbs.
The general philosophical underpinning of Chinese medicine and use of TCM is that of
‘holistic medicine’. Thus clinicians in China pride themselves on treating the person as a
whole, including body, mind, and spirit. TCM formulations are typically selected based
upon the purported individual properties of the herbs, and their abilities to work in
complementary fashion with other herbs in the mixture. For example, a wide-spread strategy
underlying TCM treatment of CHB is to: (i) relieve anxiety and symptoms and improve the
quality of life of the patients; (ii) alleviate inflammation; (iii) arrest hepatic fibrosis; (iv)
improve immune function; and (v) improve lipid metabolism. Somewhat analogous is the
recent recommendation of the “polypill” to manage cardiovascular disorders and risk
factors3.
Standard Modern Medical Treatments for CHB
Currently, the approved remedies worldwide for patients with CHB are interferon (IFN) and
lamivudine (LAM) or other nucleoside analogues (e.g. adefovir, entecavir, tenofovir) 4.
However, the overall therapeutic efficacy of IFN is limited by its inconvenient parenteral
route of administration, unpleasant side effects, and expense. Although patients treated with
lamivudine or other nucleoside analogues generally respond well to the medication and
experience fewer side effects, in many cases the HBV replication increases markedly as
soon as the treatment is stopped. Furthermore, the emergence of drug resistance and viral
variation limit their efficacy as therapeutic agents for CHB, and the newer nucleoside
analogues are prohibitively expensive for many patients. Thus, currently, in mainland China,
IFN and LAM are the most commonly used Western remedies.
Goals of the Review
Despite the availability of IFN and/or nucleoside analogues, almost 80% of the patients with
CHB in China rely on TCM therapy. In recent decades, a number of clinical trials have been
performed in China to assess the therapeutic efficacy and safety of TCM for treating CHB
infection. Studies have assessed the effects of TCM on CHB, both alone, and in combination
with medicines of western origin. Results from the trials suggest that some TCM may indeed
be effective therapeutic agents for the treatment of CHB. These encouraging findings have
prompted investigations in both Asian and western countries to explore the potential of
TCM in the treatment of liver diseases.
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The goals of this review are to summarize and analyze results of recent RCTs employing
TCM in the treatment of CHB. Furthermore, a search was performed to determine which
individual herbs are used most frequently in TCM formulations, and which appear to have
the greatest efficacy in treating CHB. This information may be used to begin to determine
which herbs or combinations of herbs possess the most therapeutic potential for treatment of
CHB. A portion of this review has appeared in abstract form (available on line at
http://www.isvhld2009.org/secondary.php?section=Abstracts) and was presented at the 13th
International Symposium on Viral Hepatitis and Liver Disease, March 22, 2009,
Washington, DC [oral presentation 92].
Data Bases Searched and Search Criteria
Searches of publications in the China National Knowledge Infrastructure (CNKI) and in
PubMed were performed. Both searches were limited to trials reported between Jan., 1998
and June, 2008. The search key words used were combinations of TCM, herbs, single herb,
herbal extract, plant and hepatitis B. All publications, which were written in either Chinese
or English, were downloaded, read and critically reviewed.
Clinical trials studied included randomized controlled trials (RCTs), non-randomized
controlled clinical trials (non-RCTs), and summaries of clinical experience. The diagnostic
criteria for CHB were positivity for serum HBsAg and/or HBeAg for more than six months,
with elevated levels of serum alanine aminotransferase (ALT). Studies were selected for
analysis if they named the individual herbs in the TCM formulation, and if there was an
objective outcome measure (normalization in serum ALT, loss of serum HBeAg, and/or
clearance of serum HBV DNA). If the studies matched the criteria outlined above, the
names of the herbs were input into a database. The number of times individual herbs were
used in different TCM formulations was recorded to determine the frequency with which
particular herbs were used in TCM formulations used to treat CHB.
For assessing the effectiveness of TCM formulations in the treatment of CHB, the effects of
TCM on CHB were compared to the effects of IFN and LAM on CHB. Use of IFN required
therapy at a dose of at least 3 million units, administered three times a week for at least three
months. Because of the existence of different forms of IFN, we included studies in which
not only IFN α, but also IFN α-1b, IFN α -2b, or IFN α -2a were used. Use of LAM required
its administration at a dose of at least 100 mg, administered once daily for at least thirty
consecutive days. The review summarizes not only the effects of TCM on CHB, but also any
reported side effects associated with therapy.
Due to the length limitations of this review, studies that assessed single herbs, or single
herbal extracts in the treatment of CHB are not included. Although we used single herb and
herbal extract as one of our search terms, these were used mainly to determine the total
number of publications related to TCM and CHB that have been published in the past
decade. We plan to write a review regarding the effects of single herbs as well as single
herbal extracts in the treatment of CHB at a later date.
RCTs in humans were included, regardless of whether they were single blind, double blind
or not blinded, which compared the therapeutic efficacy of (i) TCM formulations only
versus IFN or LAM or (ii) TCM formulations plus IFN or LAM versus IFN or LAM on
CHB. We focused on comparing the results of the virological response (loss of serum
HBeAg and/or clearance of serum HBV DNA) and normalization of serum ALT levels at
the end of treatment among the groups under comparison.
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Methodological Quality and Statistical Analysis of RCTs
The methodological quality of the RCTs included in our study was assessed by the method
of Jadad 5. The scores range from one to five, one or two being considered as low quality
trials, and three to five as high quality. The Review Manager statistical software package
(version 4.2, Biostat, Englewood, NJ) was used for the statistical analysis. According to
usual standards for fitting to random-effects model [i.e., when the p value of heterogeneity
of the results between two group trials is less than 0.1, or even when the p value is greater
than 0.1, but the I2 parameters between two groups is greater than 50 ~ 70%], we chose the
random-effects model to perform data analysis. Dichotomous data were presented as odds
ratios (OR) and continuous outcomes as weighted mean differences, both with 95%
confidence intervals (CI).
Results
General Summary of Results
A total of 643 papers that fitted our criteria for inclusion were retrieved from CNKI and
PubMed. 596 of the papers were in Chinese, and 47 were in English. Of these 643 papers,
487 were clinical trials, 80 were pre-clinical experimental studies and 76 were summaries of
non-randomized clinical experience. Of 487 clinical trials, 356 were RCTs and 131 were
non-RCTs. Of the 643 papers published between Jan 1998 to Jun 2008, the majority, (over
92%) were retrieved from CNKI (Fig. 1). For reasons unknown, the number of papers from
China related to TCM use in the treatment of CHB has decreased in recent years (from 2006
to July, 2008; see Fig. 1).
Of the 487 clinical trials, 434 were excluded because they were not RCTs or otherwise did
not meet our inclusion criteria, or requisite data were not available. Thus, 53 RCTs were
identified that reported random allocation of patients with CHB to treatment with TCM
formulations (thereby meeting our inclusion criteria). Figure 2 provides a summary of
studies reviewed and included or excluded from analysis. As regards assessment of the TCM
employed in this published work, 76 publications described clinical experiences but did not
describe clinical trials, whereas 563 described clinical trials. However, 333 of these were
also excluded for one or more of the reasons given above. Thus, results of 230 trials were
used to describe the TCMs used. Fifty three RCTs were analyzed to determine the
effectiveness of TCM on CHB. The compositions of traditional medicines in each
formulation of TCM were different among RCTs, but approximately 50 ~ 60% of the herbs
were the same across different formulations. Details of these herbs and relevant references
are provided in the supplementary material, available on-line at [to be inserted by
Hepatology editor].
Of the 53 RCTs included in our analysis, none reported the methods used for achieving
prospective random allocation to treatment groups, allocation concealment, nor if they were
double-blind, single-blind, or unblinded. Sixteen (27%) of the 53 RCTs had Jadad scores of
three, and the remaining 37 (73%) had scores of two. Only 13 trials reported long-term
follow up results, therefore we did not include data on long-term effects of TCM in this
review.
Forty-eight of the 53 RCTs used clearance of HBV DNA as a measurement of effectiveness
for treating CHB. PCR methods were used to measure HBV DNA in 23 RCTs (lower limit
of detection = 1.0 × 103 copies/mL); spot hybridization methods were used in 2 RCTs
(lower limit of detection not reported); in the remaining 23 RCTs, the methods used for
HBV DNA measurement were not reported.
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Twenty of the 53 trials reported whether or not patients experienced adverse events when
taking TCM formulations. Of these 20 trials, 13 RCTs compared TCM with IFN, whereas 7
RCTs compared TCM with LAM. No serious adverse effects of TCM were reported. The
majority of adverse events were reported by patients who received IFN during their
treatment.
Compared with the number of clinical trials performed (487), the numbers of pre-clinical
studies (which includes studies in animal and cell models) reporting the effects of TCM on
CHB were much lower in number (80). This paucity of pre-clinical studies may be related in
part to the difficulty in identifying the individual herbs in TCM formulations, coupled with
the traditional and widespread belief that TCM have a long history of use, and are therefore
safe. Furthermore, a lack of infrastructure and/or funding for preclinical research in China
may have contributed to the dearth of pre-clinical studies undertaken.
Analysis of TCM Formulations
Of 487 clinical trials and 76 summaries of clinical experience, 230 trials met our criteria for
inclusion in our analysis of the TCM formulations (Fig. 2). A goal of this analysis was to
determine which particular herbs were used most frequently. A total of 203 different kinds
of herbs were included in 230 TCM formulations for treatment of CHB. In Table 1, we list
the 30 herbs that were included most frequently in the 230 TCM formulations (the
references associated with Table 1 are listed in Suppl. Ref.1). For example, the herb used
most often, Mongolian milkvetch root (Huang Qi), was used 143 times in 230 different
formulations; the herbs used least frequently, Radix polygoni multiflori (He Shou Wu), and
Herba scutellariae (Ban Zhi Lian), were used in only 23 of 230 formulations. Among the
230 formulations we reviewed, each formulation contained an average of 9 ingredients
(range: 3-18).
Summary of Effects of TCM on CHB Infection
(i) TCM +/−IFN versus IFN—Thirty-four RCTs (n = 3656) compared TCM formulations
to IFN in the treatment of CHB. In 16 of these 34 trials, responses in patients receiving TCM
only (n = 1918) were compared to those treated with IFN. (Selected demographics of
subjects and design characteristics of included RCTs are summarized in Suppl. Table 1 and
2, and the associated references are listed in Suppl. References associated with Suppl.
Tables). The average size of the trials was 120 patients (range: 47 to 248); the age at entry
was 34.1 ± 2.8 (mean ± SD) years; the proportion of male patients was 63.7 ± 16.3%; the
mean duration of treatment was 145 ± 72 days with range 90 - 360 days (Table 2). In 18 of
the 35 trials, patients received TCM plus IFN (n = 1738) and results were compared to
patients treated with IFN alone, (Selected demographics of subjects and design
characteristics of included RCTs are summarized in Suppl. Table 2 and 3, and the associated
references are listed in Suppl. References associated with Suppl. Tables). In these trials, the
average number of subjects studied was 91, varying from 40 to 268; the mean age was 36.6
± 2.8 years; the proportion of male patients was 70.3 ± 10.9%; the mean duration of
treatment was 147 ± 85 days with range 60 - 360 days (Table 2).
(ii) TCM +/− LAM vs LAM—Twenty RCTs (n = 2271) comparing the effects on CHB of
TCM formulations and LAM were identified. In 6 of the 20 trials, patients received TCM
only (n = 723), and their responses were compared to those of patients receiving LAM
alone. (Selected demographics of subjects and design characteristics of included RCTs are
summarized in Suppl. Table 4; the associated references are listed in Suppl. References
associated with Suppl. Tables). The average size of these trials was 120 patients, varying
from 60 to 328; the mean age was 38.4 ± 3.8 years; the proportion of male patients was 54.0
± 6.3%; the mean duration of treatment was 150 ± 67.1 with range 30 - 180 days (Table 2).
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In 14 of the 20 trials, patients received TCM plus LAM (n = 1548) and patient responses
were compared to those given LAM only. (Selected demographics of subjects and design
characteristics of included RCTs are summarized in Suppl. Table 4 and 5, the associated
references are listed in Suppl. References associated with Suppl. Tables.) The average size
of these trials was 110 subjects, varying from 40 to 212; the mean age was 34.4 ± 5.9 years;
the proportion of male patients was 65.4 ± 13.0%; the mean duration of treatment was 313 ±
155 days, with range 90 - 720 days (Table 2).
Meta Analysis of Data
We performed a meta-analysis of all the results from the 53 included RCTs, yielding a total
of 12 comparisons (Suppl. Analyses 1 to 12). These results are summarized in brief in Table
2.
(i) TCM versus IFN treatment—Compared with IFN treatment alone TCM formulations
had a significantly better effect on normalizing serum ALT, (OR 2.42, 95% CI 1.51 - 3.89, p
= 0.0003), and were equivalent in reducing serum HBeAg (OR 1.60, 95% CI 1.00 - 2.54, p =
0.07) and clearing serum HBV DNA (OR 1.31, 95% CI 0.87 - 1.98, p = 0.20).
(ii) TCM plus IFN versus IFN treatment alone—Compared with IFN treatment alone,
a combination of TCM formulations plus IFN showed a significant effect on reduction of
serum HBeAg (OR 2.17, 95% CI 1.74 - 2.72, p < 0.00001), improved clearance of serum
HBV DNA (OR 2.05, 95% CI 1.59 - 2.65, p < 0.00001), and improved normalization of
serum ALT (OR 3.07, 95% CI 2.35 - 4.00, p < 0.00001).
(iii) TCM versus LAM treatment—Compared with LAM treatment alone (Table 2),
TCM formulations showed no significant difference in reducing serum HBeAg (OR 1.57,
95% CI 0.60 - 4.12, p = 0.36) or clearance of serum HBV DNA (OR 1.20, 95% CI 0.61 -
2.36, p = 0.59). For serum ALT normalization (Table 2), TCM formulations were more
effective than LAM (OR 1.96, 95% CI 1.15 - 3.32, p = 0.01).
(iv) TCM plus LAM versus LAM treatment—Compared with LAM treatment alone
(Table 2), the combination of TCM plus LAM showed a highly significant effect on
reduction of serum HBeAg (OR 2.54, 95% CI 1.95 - 3.32, p < 0.00001), clearance of serum
HBV DNA (OR 3.20, 95% CI 2.09 - 4.92, p < 0.00001) and normalization of serum ALT
(OR 3.40, 95% CI 2.45 - 4.70, p < 0.00001).
We also performed similar analyses on the 16 RCTs of higher technical quality (Jadad score
=3). The direction and pattern of the results were similar, although, as might be anticipated
from a meta-analysis involving a smaller number of total subjects (n=731), the significance
of effects was smaller and the CI’s were larger.
Herbs found in TCM Formulations Showing Promise for Treatment of CHB
Based on our review of the literature, we documented and ranked the top thirty individual
Chinese herbs that were used in TCM formulations for the treatment of CHB patients in
China (Table 1). Because the majority of herbs were administered in combination with other
herbs in TCM formulations, it is not possible to determine exactly which individual herbs in
the formulation have the greatest therapeutic potential in the treatment of CHB. However,
based upon our review of all the papers included in our literature searches and upon the prior
knowledge and experience of Drs. Zhang and Li, we have selected four herbs that seem
worthy of additional, in-depth study. Below is a brief commentary on these 4 herbs.
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The leguminous plant Astragalus (Fig. 3A), which is the herb most frequently used in TCM
formulations for CHB (Table 1), has received a lot of attention by Chinese physicians
because of its purported immune-modulating and anti-viral properties. Its principal
ingredients include astragalosides and astragals polysaccharides, of which the latter has
received particular attention for treatment of CHB.
In 2003, Zou et al 6 described anti-HBV activity of astragulus extracts in vitro. Previously,
Huang et al 7 reported that the extract of astragalus inhibited HBV reverse transcriptase
(HBV-RT) and deoxyribonucleic acid polymerase (DNA-DNAP) in a duck model of HBV.
A more recent in vitro study indicated that astragalus strongly inhibits the secretion of
HBsAg and HBeAg in the HepG 2.2.15 cell line8.
In 1995, a clinical RCT reported by Zhang et al 9 demonstrated that CHB patients treated
with astragalus polysaccharides showed improved normalization of serum ALT, reduced
serum HBeAg and clearance of serum HBV DNA when compared to control patients. It was
also noted that astragalus polysaccharides alone induced an increase in endogenous IFN
levels in vivo.
Polygonum cuspidatum ( Hu Zhang )
Polygonum cuspidatum (Fig. 3B), which is ranked in the top five of individual herbs used
most frequently in TCM formulations for CHB (Table 1), belongs to the plant genus
polygonaceae. Polydatin, the major active component in polygonum cuspidatum, is the most
common herbal medicine used to treat patients with liver diseases in China 10, 11. Huang et
al reported that Polygonum cuspidatum and one of its known active ingredients (resveratrol)
strongly suppressed lipid peroxidation and protected rat hepatocytes injured by CCL4 in
vitro 12. Studies by Zhou et al determined that resveratrol was effective in inhibiting HBV
in HepG2.2.15 cells, perhaps by inhibiting HBV replication, and by inducing apoptosis 13.
There are, however, no clinical trials in the literature related to the use of the individual herb
Polygonum cuspidatum in treatment of CHB. Resveratrol is also found in other plants,
including the skin of red grapes. The beneficial health effects of drinking red wine have
been ascribed to resveratrol. A recent review documents growing evidence that resveratrol
can prevent or delay the onset of a number of cancers, heart diseases, chemical and ischemic
- induced injuries, inflammation and viral infections 14. Furthermore, Gedik et al reported
that resveratrol reduces oxidative stress and histological alterations induced by liver
ischemia/reperfusion 15.
Radix et rhizoma rhei (Da Huang)
Radix et rhizoma rhei (Fig. 3C) also belongs to the plant genus polygonaceae. It ranks
number 15 of the top 30 herbs (Table 1) used in TCM formulations to treat CHB. Emodin is
one of the major active compounds of Radix. In 2007, Dang et al showed that emodin had
time-and concentration-dependent inhibitory effects on HBV in vitro 16. As early as 1997,
Huang et al 15 reported that Radix extract significantly inhibited hepatic B virus reverse
transcriptase (HBV-RT) and deoxyribonucleic acid polymerase (DNA-DNAP) in a duck
HBV-model. In recent years, studies from both Liu and Li demonstrated that ethanol
extracts of Radix can markedly inhibit the secretion of HBsAg and HBeAg in HepG2.2.15
cells 17, 18. Moreover, Li’s studies suggest that the compound anthraquinone chrysophanol
8-O-β-D-glucoside is the major active compound in Radix extract, and that this could be a
promising candidate as a new anti-HBV drug.
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Phyllanthus urinaris (Ye Xian Zhu)
The plant of the genus Phyllanthus urinaris (Fig. 3D) is a highly valued Chinese herb that
has been used in TCM formulations to treat chronic liver disease for centuries. Phyllanthus
belongs to the family euphorbiaceae, which has many members. Its high cost may limit its
use by Chinese physicians in TCM formulations, which could explain why it is number 26
on the list of most frequent herbs in TCM for CHB (Table 1). However, phyllanthus is one
of the herbs generally acknowledged in China to be of greatest value for treatment of CHB.
A number of classes of compounds, including alkaloids and flavonoids, have been isolated
and characterized from phyllanthus. In 1997, M. Ott et al 19 reported that the phyllanthus
amarus plant suppressed HBV mRNA transcription in Huh-7 cell lines. In recent years, Eun
et al 20 demonstrated that ellagic acid, a flavonoid isolated and purified from phyllanthus,
could block the immune tolerance caused by HBeAg in HbeAg-producing transgenic mice.
As described above, a number of RCTs looking at the therapeutic effectiveness of
phyllanthus in the treatment of CHB have been performed. A systematic review of
phyllanthus for CHB virus infection, performed in 2001 by J. Liu 21, concluded that
phyllanthus species may have positive effects on antiviral activity and liver biochemistry in
chronic HBV infection, and that further trials are warranted.
Discussion
Summary of Effectiveness of TCM in Treating CHB
To summarize, our review of the recent Chinese literature revealed that some TCM may
have beneficial therapeutic effects on CHB. Our meta-analysis (Table 2) suggests that in
patients with CHB (i), TCM have a similar curative effect as IFN/LAM on antiviral activity
as evidenced by the loss of serum HBeAg and HBV DNA; (ii) TCM have a better effect on
normalization of serum ALT; and (iii) TCM enhance IFN and LAM anti-virus activity and
improvement of liver function. Of note is that there were no reported serious adverse events
associated with the combinations of TCM studied. As used in China, these formulations
seem to be very well tolerated, although many reports did not include data on adverse effects
of therapy. Taken together, these results suggest that further study of TCM in the treatment
of CHB is warranted.
It must be acknowledged, however, that the methodological quality of the trials evaluating
the effect of TCM on CHB was generally not high: 37/53 (70%) of the RCTs included in
this review were scored as having mediocre methodological quality [Jadad scores = 2]. No
trial was identified as a multi-center, large-scale, prospective, double-blinded, controlled
randomized trial. Furthermore, only 13 of the 53 RCTs performed long-term follow up
studies. Nevertheless, when we repeated our analysis on the effectiveness of TCM
formulations on CHB using only those RCTs that scored at least 3 on the Jadad scale (n = 16
trials), the results were not significantly different from those of lower methodological
quality.
The possibility of publication bias in the reporting of results of clinical trials is always of
concern. It was certainly a concern to us when performing the meta-analyses in this review.
Obviously, the purported effectiveness of TCM formulations on CHB could be exaggerated
if only positive results were published. To try to assess whether there was major publication
bias, funnel plots were done when 9 or more studies were available for analysis. These plots
did not show appreciable asymmetry [See Supplemental Meta-analyses 1-9], suggesting that
there was not major publication bias. However, we emphasize the importance that
investigators submit, and that journal editors publish, the results of negative, as well as of
positive, clinical trials.
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Traditional herbal medicines have been used in China for more than two thousand years, and
they now are being used increasingly worldwide. The goal of this review was to summarize
and analyze results of recent clinical trials utilizing TCM in the treatment CHB in China to
help ascertain which herbs, or combination of herbs, possess the most therapeutic potential
for treating CHB, and warrant further study. However, there are inherent difficulties
associated with this type of analysis that are related to differences in philosophy in Chinese
and Western Medicine.
Although therapeutics historically have been based upon observation and retrospective
analyses, both in the occident and the orient, during the past 50 years, the study and approval
of new ethical drugs, especially in western countries, has required persuasive data on
efficacy and acceptable risks of toxicity. Such data generally are obtained from prospective,
double-blind, placebo-controlled, large registration trials. The results of such studies
notwithstanding, millions of people in the occident continue to use herbal products and
dietary supplements, including those with chronic viral hepatitis 22 and other liver diseases.
Thus, the actual practices of persons in China and the west are not so very different, despite
the great cultural divides. Use of TCM in China is based on clinical observations and
wisdom accumulated over centuries of use and practice. A difficulty in interpretation is that,
typically, numerous herbs are used in combination in TCM formulations to attack a disease
process in manifold ways. Each herbal product within the TCM formulations may have
several different active ingredients. Furthermore, the content and biological activities of
these ingredients can be influenced by many things, including where the herb was grown,
and at what season it was harvested. Consequently, it is difficult to compare the results from
TCM studies because different batches of the same TCM formulations could have somewhat
different properties. This, in turn, makes it difficult, if not impossible, to apply western
standards and analyses to studies of TCM. Nevertheless, the integration of TCM with
modern technologies and therapies is a pre-requisite to further understanding the potential
therapeutic benefits of TCM in the treatment of CHB.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Numbers of publications reporting studies of TCM on HBV in China knowledge
infrastructure from Jan., 1998 to June, 2008.
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Summary of studies reviewed and those selected for or excluded from this meta-analysis.
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Four typical herbs used in TCM for anti-HBV activity. A: Astragalus (Huang Qi), a
leguminous plant; B: Polygonum cuspidatum (Hu Zhang) belonging to the plant genus
polygonaceae; C: Radix et rhizoma rhei (Da Huang) also belonging to the plant genus
polygonaceae; D: Phyllanthus urinaris (Ye Xian Zhu) belonging to the plant of the genus
Phyllanthus urinaris. Note: The processed herb (Yin pian) is shown in the small picture.
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Table 1
The thirty herbs used most often for CHB in recent reports from China
English herbal name (Chinese pinyin) Frequency of use in
230 formulas
Total numbers of patients given the
herb in these reports
Astragalus (Huang Qi) 143 12674
Salvia miltiorrhiza (Dan Shen) 135 10784
Largehead atractylodes rhizome (Bai Shu) 113 8304
Radix bupleuri (Chai Hu) 108 9888
Polygonum cuspidatum (Hu Zhang) 102 8700
Oldenlandia diffusa
(Bai Hua She She Cao)
92 9198
Radix glycyrrhizae (Gan Cao) 85 7219
Herba artemisiae capillaries (Yin Chen) 79 7545
Radix paeoniae rubra (Chi Shao) 71 5580
Radix cureumae wenyujin (Yu Jin) 64 6323
Poria (Fuling) 60 4528
Radix paeoniae alba (Bai Shao) 60 4040
Radix angelicate sinensis (Dang Gui) 56 4391
Radix codonopsis (Dang Shen) 46 3308
Radix et rhizoma rhei (Da Huang) 38 3719




Lycium chinensis mill (Gou Qi Zi) 32 3480
Fructus ligustri lucidui (Nv Zhen Zi) 32 3319
Herba sedi sarmentosi (Chui Pen Cao) 29 2365
Radix sophorae flavescentis (Ku Shen) 28 1697
Hawkthorn (Shan Zha) 28 2805
Fructus gradeniae (Zhi Zi) 26 2475
Pericarpium citri reticulatae (Chen Pi) 25 1959
Semen coicis (Yi Yi Ren) 25 2767
Phyllanthus urinaris (Zhen Zhu Cao) 24 2071




Herba scutellariae (Ban Zhi Lian) 23 2239
Radix polygoni multiflori (He Shou Wu) 23 2313
Abbreviations: CHB, chronic hepatitis B.
References for Table 1 are listed in Suppl. Ref. 1
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